Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry.
about
Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disordersAlternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: a network meta-analysis and systematic reviewComparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disordersInflamm-Aging of Hematopoiesis, Hematopoietic Stem Cells, and the Bone Marrow MicroenvironmentWhy has demand for platelet components increased? A reviewDetectable clonal mosaicism from birth to old age and its relationship to cancerManagement of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.A nationwide non-interventional epidemiological data registry on myelodysplastic syndromes in Lebanon.Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.Prevalence and possible causes of anemia in the elderly: a cross-sectional analysis of a large European university hospital cohort.Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic reviewRomiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.Clinicohematological and cytogenetic profile of myelodysplastic syndromes in Pakistan-compare and contrast.A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry.Myelodysplastic syndromes: diagnosis, prognosis, and treatment.Incidence of myelodysplastic syndrome in Japan.Clinical utility of lenalidomide in the treatment of myelodysplastic syndromesUnderestimation of myelodysplastic syndrome incidence by cancer registries: Results from a population-based data linkage study.Cytokine expression patterns and mesenchymal stem cell karyotypes from the bone marrow microenvironment of patients with myelodysplastic syndromes.Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes.Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes.Incidence and Burden of the Myelodysplastic Syndromes.The incidence of myelodysplastic syndromes in Western Greece is increasing.Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders.Myelodysplastic Syndromes and Iron Chelation TherapyWhat's all the fuss about? facts and figures about bone marrow failure and conditions.The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy.New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.Are myelodysplastic syndromes underdiagnosed in Poland? A report by the Polish Adult Leukaemia Group.Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management.A case of mandibular osteomyelitis in a patient with chronic myelomonocytic leukaemia.Myelodysplastic syndromes in South America: a multinational study of 1080 patients.Techniques for detecting chromosomal aberrations in myelodysplastic syndromesThe role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromesResults from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain.[Myelodysplastic syndromes. Epidemiology, molecular and morphological characteristics and risk stratification].The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany.
P2860
Q24186615-06FF47C0-85D5-4EE2-931A-D54DB08F5BDEQ24186703-0F5ACFF8-D633-40AA-BD67-404F0D8B2F05Q24187692-D71FB931-F1A3-4CA6-BFA2-1ED0D083DCBBQ28074446-ACC962CA-2CF4-49E2-9B43-7086B5B5C3E4Q28249969-E0FC06E8-5BCE-49A1-B4BE-0C65A054107BQ28385149-D4507F78-FE88-4216-887D-A27329929F7FQ30235355-4E4E62CD-B8E4-4620-8539-AFE6D365621AQ31074791-816E6BF2-8380-4353-BF1C-6F5CF9E79B07Q33408873-E3BFD0F9-9A25-4235-A057-16C98C40F443Q33416891-347E6F4E-30EF-49A2-BA5A-62E913025FD5Q33436416-35909FD7-1349-4BA0-BE2D-404D2D91B1A0Q33442715-BD88F950-3D68-4AD2-8C22-9EC21A4D9A60Q33651786-F901E486-6F37-4AAD-AE5D-60252B831CB8Q33877952-44E068E9-E44F-4C11-9B69-60FFEAE6E5DAQ34389508-01296FA5-8617-4702-BF15-18FE0BACFE8CQ34421751-BF801860-1398-48BA-8242-B553FF38573AQ34783754-E056B99A-44D4-41CE-A777-EAF63B7C8CA4Q35124447-49835502-E344-490F-BACB-C18FC2B7A65BQ35240550-70A16661-8D12-4118-8798-EC52369B54F5Q35317026-48902F64-BB45-4A80-896C-E689690F327CQ35571031-31D7AAE0-C00A-442F-9259-4EA9175A1A19Q36006077-C034D51E-E4FF-4019-92A5-483A7B4183ABQ36907039-1C4A3B24-2458-4523-ABDC-E79F8F0F6CE4Q37263146-18EFA1C0-5B19-44B8-9973-8061A4059E0BQ37265484-A3B8DA5A-3F6E-4DBC-BAEE-FD0FDBDA63A1Q37677229-245F5DBB-04D6-42B0-BAE1-CEA3F14C0741Q38039381-891D6887-BBC4-4DEC-A776-B315FAC4197BQ38078427-B5677DC1-2530-4470-B535-13CBA1406C41Q38225750-2693941F-E1E1-43C0-96F6-AEF6613BE311Q38687894-7085A7E4-6B65-4B39-B8DF-F06395F28312Q39325327-A0A182D2-4E12-46D6-93BD-A7C5D8C6073EQ40420210-7FAEF662-D262-4BB9-BE6F-5ECB201855AEQ40559213-8C8CA92D-FDF7-414B-994B-C8A26BDD3CA3Q40806109-7065B6B1-776A-4D42-AF6E-AB7EDA9F08BEQ41791233-1546B5BD-C4CE-4717-8974-D3ECAD898334Q41856578-94A8EFB0-5434-4B1E-BD08-C95928B90324Q42673156-C946ABC2-39DB-4B2E-A52F-7CC7B51B1AFDQ43065868-04EC2DF9-9235-4116-852F-6BF33B61114DQ44325617-A3664943-AF58-4EFB-A68F-F1A384964F6AQ44895438-4B1EF870-FCD0-4682-ADD0-87B47AAF3C98
P2860
Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Incidence and prevalence of my ...... m the Düsseldorf MDS-registry.
@ast
Incidence and prevalence of my ...... m the Düsseldorf MDS-registry.
@en
type
label
Incidence and prevalence of my ...... m the Düsseldorf MDS-registry.
@ast
Incidence and prevalence of my ...... m the Düsseldorf MDS-registry.
@en
prefLabel
Incidence and prevalence of my ...... m the Düsseldorf MDS-registry.
@ast
Incidence and prevalence of my ...... m the Düsseldorf MDS-registry.
@en
P2093
P50
P1433
P1476
Incidence and prevalence of my ...... m the Düsseldorf MDS-registry.
@en
P2093
Corinna Strupp
Judith Neukirchen
Rainer Haas
Wilma M Schoonen
P304
P356
10.1016/J.LEUKRES.2011.06.001
P577
2011-06-25T00:00:00Z